Healthcare Sales & Marketing Network News: monoclonal

Searching News Database: monoclonal

Your search returned too many results! The most recent 500 items are shown below:

HSMN NewsFeed - 6 Aug 2026
Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Jul 2026
Mentari Therapeutics Appoints Industry Veteran Greg Divis as Chief Executive Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 17 Jun 2026
Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 May 2026
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 23 Apr 2026
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Biopharmaceuticals Licensing

HSMN NewsFeed - 16 Apr 2026
Harbour BioMed Appoints Dr. Adam Zong as President
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Mar 2026
Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation
Biopharmaceuticals Personnel

HSMN NewsFeed - 17 Mar 2026
VST BIO Corporation Announces Series A Financing to Advance VB-001 and Adds William Sessa to Board of Directors
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 25 Feb 2026
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Jan 2026
ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
Biopharmaceuticals Generics Neurology FDA

HSMN NewsFeed - 9 Oct 2025
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 5 Sep 2025
Roche Receives CE IVDR Approval for HER2 (4B5) Companion Diagnostic Test to Identify HER2-ultralow Breast Cancer and Biliary Tract Cancer Patients
Diagnostics Oncology Regulatory

HSMN NewsFeed - 25 Aug 2025
Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4R?) for Atopic Dermatitis Achieve Primary Endpoints
Biopharmaceuticals

HSMN NewsFeed - 16 Jun 2025
Solu Therapeutics Appoints Enda Moran, PhD, MBA as Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Apr 2025
Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic Malignancies
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 17 Mar 2025
Surf Bio Appoints Industry Veteran Doug Hecker as Head of Technical Operations
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 19 Feb 2025
Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Jan 2025
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 17 Jan 2025
FDA Approves LUMAKRAS(R) (Sotorasib) in Combination with Vectibix(R) (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jan 2025
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX(R) (bimekizumab-bkzx)
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 8 Jan 2025
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 25 Oct 2024
Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab
Biopharmaceuticals Dermatology

HSMN NewsFeed - 3 Oct 2024
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Aug 2024
Sanyou Bio Launches Comprehensive Monkeypox Product Line
Biopharmaceuticals Product Launch

HSMN NewsFeed - 6 Aug 2024
NeuroTherapia Raises $12.3M in the First Close of its Series B Financing
Biopharmaceuticals Neurology Venture Capital

HSMN NewsFeed - 29 Jul 2024
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jun 2024
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 May 2024
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili(TM). Enters U.S. Ophthalmology Market
Biopharmaceuticals Generics Ophthalmology FDA

HSMN NewsFeed - 10 Apr 2024
TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 18 Mar 2024
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 Feb 2024
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Jan 2024
TORL BioTherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Significant Progress of its Oncology Clinical Programs
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Dec 2023
Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 Oct 2023
FDA Approves Novartis Cosentyx(R) as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Sep 2023
Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Aug 2023
Zumutor Biologics Inc Announces FDA Clearance of IND Application of ZM008, a Novel Monoclonal Antibody Drug Against Multiple Solid Cancers
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 6 Jun 2023
Acepodia Secures $100 Million Series D Financing to Advance
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 3 May 2023
Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 21 Feb 2023
Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 4 Jan 2023
Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Jan 2023
ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Dec 2022
Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy
Diagnostics Biopharmaceuticals

HSMN NewsFeed - 30 Nov 2022
Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy
Biopharmaceuticals Personnel

HSMN NewsFeed - 23 Nov 2022
BioMarin Announces Advancements in FDA Review of ROCTAVIAN(TM) (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Sep 2022
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Aug 2022
Alternative Pathway Blocker Anti-Bb Antibody (NM8074) Receives US FDA Clearance to Start Efficacy Trial in C3 Glomerulopathy (C3G) Patients
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Aug 2022
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jul 2022
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Jul 2022
Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Jun 2022
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Jun 2022
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Biopharmaceuticals Dermatology

HSMN NewsFeed - 24 May 2022
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 20 Apr 2022
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
Biopharmaceuticals

HSMN NewsFeed - 25 Feb 2022
Gamifant (emapalumab) recommended for approval in China for treatment of primary haemophagocytic lymphohistiocytosis (HLH)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 3 Jan 2022
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 21 Dec 2021
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Biopharmaceuticals Dermatology

HSMN NewsFeed - 9 Dec 2021
Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia(R) and Xgeva(R)
Biopharmaceuticals Generics Licensing

HSMN NewsFeed - 7 Dec 2021
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Dec 2021
Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Dec 2021
Harbour BioMed Appoints Mr. Weihao Xu as Chief Strategy Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Dec 2021
UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 8 Nov 2021
Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Oct 2021
FDA Expands Approval of Dupixent(R) (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Oct 2021
FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Sep 2021
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Sep 2021
Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 30 Aug 2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Aug 2021
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Biopharmaceuticals Dermatology

HSMN NewsFeed - 5 Aug 2021
KalGene Pharmaceuticals Inc. an Alzheimer's focused company using a next generation engineered drug candidate, has appointed new leadership
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 3 Aug 2021
SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Jul 2021
SynOx Therapeutics Strengthens Team with Appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Jul 2021
Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Jul 2021
Sirnaomics Secures $105 Million in Series E Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 22 Jun 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE(R) drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 14 Jun 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Apr 2021
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Mar 2021
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Feb 2021
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
Biopharmaceuticals

HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Feb 2021
New Scientific Publications Show Diadem's Blood-Based AlzoSure(R) Biomarker Test Can Predict Which Patients Will Progress to Alzheimer's Disease Years Before Symptoms Occur
Diagnostics Neurology

HSMN NewsFeed - 19 Jan 2021
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Dec 2020
AIVITA Biomedical Closes $25 Million Financing Round
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Biopharmaceuticals

HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Dec 2020
Obiltoxaximab Receives Marketing Authorization From European Commission For The Treatment Of Inhalation Anthrax
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Nov 2020
Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 18 Nov 2020
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 10 Nov 2020
Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma
Biopharmaceuticals

HSMN NewsFeed - 28 Oct 2020
Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19
Biopharmaceuticals

HSMN NewsFeed - 9 Oct 2020
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Oct 2020
Lilly's OVERCOME Study Reveals Nearly 80% of People Reported Improvement in Their Migraine Since Starting a CGRP Monoclonal Antibody for Preventive Treatment
Biopharmaceuticals Neurology

HSMN NewsFeed - 7 Oct 2020
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
Biopharmaceuticals

HSMN NewsFeed - 28 Sep 2020
AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 24 Sep 2020
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Sep 2020
Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 4 Sep 2020
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 4 Sep 2020
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Aug 2020
Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 24 Aug 2020
Leap Therapeutics Expands Leadership Team with Addition of Two Industry Veterans
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 12 Aug 2020
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 12 Aug 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Aug 2020
NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Aug 2020
Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
Biopharmaceuticals

HSMN NewsFeed - 29 Jul 2020
UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
Biopharmaceuticals Neurology Licensing

HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Biopharmaceuticals Dermatology

HSMN NewsFeed - 17 Jul 2020
Lilly's Mirikizumab Superior to Cosentyx(R) (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 15 Jun 2020
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jun 2020
Amplyx Pharmaceuticals Expands Executive Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Jun 2020
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment
Biopharmaceuticals

HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jun 2020
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans
Biopharmaceuticals

HSMN NewsFeed - 26 May 2020
Emgality(R) Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 May 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 7 May 2020
FogPharma Appoints Tony Gibney as Chief Financial Officer and Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Apr 2020
Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Mar 2020
Lilly's Taltz(R) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 12 Mar 2020
ImmunoPrecise Announces the Launch of PolyTope mAb Therapy(TM) to Tackle Coronavirus Pandemic
Biopharmaceuticals Product Launch

HSMN NewsFeed - 10 Mar 2020
CytRx Corporation Provides Update on Management Change
Biopharmaceuticals Oncology Neurology Personnel

HSMN NewsFeed - 20 Feb 2020
Lilly Completes Acquisition of Dermira
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 14 Feb 2020
Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Feb 2020
Avidity Biosciences Appoints Joseph Baroldi as Chief Operating Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Feb 2020
Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Jan 2020
John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Jan 2020
Lilly Announces Agreement to Acquire Dermira
Biopharmaceuticals Dermatology Mergers & Acquisitions

HSMN NewsFeed - 8 Jan 2020
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Jan 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Jan 2020
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 2 Jan 2020
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Dec 2019
Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality(R) (galcanezumab-gnlm)
Biopharmaceuticals Neurology

HSMN NewsFeed - 12 Dec 2019
European Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory

HSMN NewsFeed - 10 Dec 2019
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Dec 2019
PDL BioPharma Announces Completion of Strategic Review Process
Biopharmaceuticals

HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz(R) (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 7 Nov 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement for Octreotide Long Acting Injectable (LAI) Microsphere for Neuroendocrine Cancers and Acromegaly
Biopharmaceuticals Oncology Licensing Distribution

HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Oct 2019
Disc Medicine Expands Pipeline Focused on Hepcidin Pathway
Biopharmaceuticals Licensing

HSMN NewsFeed - 29 Oct 2019
Disc Medicine Completes $50 Million Series A Financing led by Novo Holdings A/S to Advance New Therapies Addressing Ineffective Red Blood Cell Production
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Biopharmaceuticals Cardiology Reimbursement

HSMN NewsFeed - 24 Oct 2019
Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
Biopharmaceuticals Endocrinology Regulatory

HSMN NewsFeed - 18 Oct 2019
EVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory

HSMN NewsFeed - 3 Oct 2019
New Head-to-Head Data Show Taltz(R) (ixekizumab) Superiority versus TREMFYA(R) (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 1 Oct 2019
Avidity Biosciences Appoints Sarah Boyce as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Sep 2019
CASI Pharmaceuticals Announces the Promotion of Larry Zhang to President
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Sep 2019
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Aug 2019
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Aug 2019
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology

HSMN NewsFeed - 12 Aug 2019
Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With KEYTRUDA(R) (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch

HSMN NewsFeed - 6 Aug 2019
Dupixent(R) (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 5 Aug 2019
Lilly Announces Positive Results for Emgality(R) (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
Biopharmaceuticals Neurology

HSMN NewsFeed - 2 Aug 2019
Axon Neuroscience Appoints Michal Fresser as Group CEO
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 30 Jul 2019
Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX(R) Platform Technology
Biopharmaceuticals Licensing

HSMN NewsFeed - 23 Jul 2019
Ortho Receives CE Mark for Enhanced VITROS(R) Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure
Diagnostics Cardiology Regulatory

HSMN NewsFeed - 16 Jul 2019
SurgiMab Advances SGM-101, a Novel Fluorescent Tumor-specific Antibody, Into Pivotal Phase 3 Clinical Trial to Improve Surgical Outcomes in Colorectal Cancer Patients
Diagnostics Oncology Surgery

HSMN NewsFeed - 12 Jul 2019
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality(R) (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Jul 2019
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality(R) (galcanezumab-gnlm) in Episodic Cluster Headache
Biopharmaceuticals Neurology

HSMN NewsFeed - 28 Jun 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions

HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals

HSMN NewsFeed - 14 Jun 2019
Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Biopharmaceuticals

HSMN NewsFeed - 12 Jun 2019
Sobi Acquires Emapalumab and Related Assets
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 11 Jun 2019
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz(R) (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Biopharmaceuticals Dermatology

HSMN NewsFeed - 10 Jun 2019
Oncologie Closes an $80M Series B Financing for Clinical-Stage Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 10 Jun 2019
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 31 May 2019
Rakuten Medical Opens Two New Offices In The Netherlands And Taiwan, Adding New Jobs To Strengthen And Expand Its Global Presence
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 May 2019
Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
Biopharmaceuticals Litigation Licensing

HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 May 2019
Dupixent(R) (dupilumab) Approved for Severe Asthma by European Commission
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 Apr 2019
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
Biopharmaceuticals Licensing

HSMN NewsFeed - 28 Mar 2019
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Urology Oncology

HSMN NewsFeed - 26 Mar 2019
AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Mar 2019
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Biopharmaceuticals Generics Dermatology

HSMN NewsFeed - 1 Mar 2019
CHMP Recommends Approval of Dupixent(R) (dupilumab) for Asthma Indication
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Mar 2019
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 19 Feb 2019
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Biopharmaceuticals

HSMN NewsFeed - 12 Feb 2019
U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Feb 2019
CHMP Recommends Approval of Praluent(R) (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 30 Jan 2019
CardioVax Announces Name Change to Abcentra
Biopharmaceuticals

HSMN NewsFeed - 23 Jan 2019
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 18 Jan 2019
Optimum Imaging Diagnostics (OIDx) is Proud to Announce the Release of Their First Commercial Test, the Histoplasma Capsulatum Urinary Antigen EIA Test
Diagnostics Product Launch

HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Jan 2019
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Jan 2019
EVENITY(TM) (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Dec 2018
Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 10 Dec 2018
CStone Pharmaceuticals Appoints Former MSD Global Oncology Early Development Executive Director Archie Tse, M.D., Ph.D., as the newly established SVP, Chief Translation Medicine Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Nov 2018
MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Nov 2018
FDA Approves Gamifant(R) (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Nov 2018
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality(TM) (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 13 Nov 2018
Sobi(TM) to Acquire Synagis(R) US Rights From AstraZeneca - Creates a Platform for Global Growth
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 19 Oct 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
Biopharmaceuticals Generics Oncology Regulatory

HSMN NewsFeed - 10 Oct 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi(R) in Combination with Nivolumab in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Sep 2018
Aronora's New Blood Clot Treatment Receives FDA Fast Track Designation
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Sep 2018
Lilly Receives Positive CHMP Opinion for Emgality(TM) (galcanezumab) for the Prophylaxis of Migraine in Adults
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 13 Sep 2018
IFM Therapeutics, LLC Appoints John Leonard, M.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Sep 2018
FDA to Review Supplemental Biologics License Application for Praluent(R) (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 10 Sep 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals

HSMN NewsFeed - 10 Sep 2018
BioAtla Appoints Scott Smith As President
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Sep 2018
Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Aug 2018
CBT Pharmaceuticals Announces New Leadership Structure to Drive Global Expansion
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory

HSMN NewsFeed - 8 Aug 2018
Apexigen Raises $73 Million In Series B And Series C Financings
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 24 Jul 2018
BioAtla Appoints Lawrence Fong, M.D. As Scientific Advisor
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Jul 2018
Sangamo Therapeutics to Acquire TxCell
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 13 Jul 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Jul 2018
BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer's Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 3 Jul 2018
MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals

HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 23 May 2018
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
Biopharmaceuticals Generics Licensing

HSMN NewsFeed - 15 May 2018
Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
Biopharmaceuticals Neurology

HSMN NewsFeed - 14 May 2018
Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents
Diagnostics Product Launch

HSMN NewsFeed - 10 May 2018
Lilly Announces Agreement To Acquire ARMO BioSciences
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 2 May 2018
Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 30 Apr 2018
Forty Seven Inc. Appoints Ian T. Clark to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 Apr 2018
FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Apr 2018
AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies
Biopharmaceuticals Neurology

HSMN NewsFeed - 18 Apr 2018
Tetherex Pharmaceuticals, Inc. Completes $50M Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 3 Apr 2018
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 23 Mar 2018
Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin(R)) For The Treatment Of Three Types Of Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Mar 2018
Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 5 Mar 2018
Aridis Pharmaceuticals, Inc. Appoints Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer, and Mitchell H. Rosner, Ph.D. as Vice President of Quality
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Feb 2018
AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Biopharmaceuticals Dermatology

HSMN NewsFeed - 14 Feb 2018
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 13 Feb 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals

HSMN NewsFeed - 22 Jan 2018
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 16 Jan 2018
MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Dec 2017
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
Biopharmaceuticals Oncology Litigation

HSMN NewsFeed - 26 Dec 2017
Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Dec 2017
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2017
FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Dec 2017
Forty Seven Inc. Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
Biopharmaceuticals Regenerative Medicine Oncology

HSMN NewsFeed - 4 Dec 2017
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 9 Nov 2017
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
Biopharmaceuticals Neurology

HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals

HSMN NewsFeed - 12 Oct 2017
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ(TM) (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Biopharmaceuticals Dermatology

HSMN NewsFeed - 28 Sep 2017
Regeneron and Sanofi Announce Approval of DUPIXENT(R) (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 27 Sep 2017
Foresee Pharmaceuticals and TRPharm Announce License and Distribution Agreement
Biopharmaceuticals Licensing Distribution

HSMN NewsFeed - 12 Sep 2017
Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 Sep 2017
IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine
Biopharmaceutical Neurology

HSMN NewsFeed - 8 Sep 2017
Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Sep 2017
Morphotek(R), Inc. Announces an Agreement with Fujirebio Diagnostics, Inc. to Commercialize the CA125 II Assay as a Companion Diagnostic for Farletuzumab(R)
Biopharmaceuticals Diagnostics Oncology Licensing

HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing

HSMN NewsFeed - 25 Aug 2017
Regeneron and Sanofi to Present New Analyses from Praluent(R) (alirocumab) Injection Trials at the ESC Congress 2017
Biopharmaceuticals Cardiology

HSMN NewsFeed - 17 Aug 2017
BlueRock Therapeutics Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership
Regenerative Medicine Personnel

HSMN NewsFeed - 31 Jul 2017
Amgen and Allergan Submit Biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration
Biopharmaceuticals Generics Oncology FDA

HSMN NewsFeed - 28 Jul 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha(R) (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 27 Jul 2017
Valeant Announces U.S. Launch of SILIQ(TM) (brodalumab) Injection
Biopharmaceuticals Dermatology Product Launch

HSMN NewsFeed - 17 Jul 2017
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Jul 2017
Evelo Biosciences Announces $50 Million Series B Financing and Expansion of Board and Leadership Team
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Jun 2017
EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
Biopharmaceuticals

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 May 2017
Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 22 May 2017
Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY(TM) (Romosozumab) In Postmenopausal Women With Osteoporosis
Biopharmaceuticals

HSMN NewsFeed - 18 May 2017
Amgen Submits Biologics License Application To The FDA For Erenumab
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 12 May 2017
Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 May 2017
Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Apr 2017
Regeneron and Sanofi Announce Kevzara(R) (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Apr 2017
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara(R) (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Apr 2017
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ(TM) (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 17 Apr 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Apr 2017
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Apr 2017
Roche Launches Antibody Test to Aid in Diagnosis of Challenging Prostate Cancer Cases
Diagnostics Oncology Product Launch

HSMN NewsFeed - 29 Mar 2017
FDA Approves Genentech’s OCREVUS(TM) (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 28 Mar 2017
Sanofi and Regeneron Announce FDA Approval of Dupixent(R) (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 Mar 2017
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Biopharmaceuticals Cardiology

HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Feb 2017
Kevzara(TM) (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Product Launch

HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 21 Feb 2017
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Feb 2017
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 9 Feb 2017
Syndax Appoints Richard P. Shea as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Feb 2017
Amgen Announces Repatha(R) (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 22 Dec 2016
Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
Biopharmaceuticals

HSMN NewsFeed - 22 Dec 2016
Positive Phase III Results of Genentech’s Investigational Medicine OCREVUS(TM) (Ocrelizumab) Published in New England Journal of Medicine
Biopharmaceuticals Neurology

HSMN NewsFeed - 16 Dec 2016
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 9 Dec 2016
Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA(TM) (Daclizumab Beta) for Multiple Sclerosis
Biopharmaceuticals Nerurology Regulatory

HSMN NewsFeed - 9 Dec 2016
Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at the Clinical Trials on Alzheimer's Disease (CTAD) 2016 Meeting
Biopharmaceuticals Neurology

HSMN NewsFeed - 30 Nov 2016
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 25 Nov 2016
Macrocure Announces New Date for Special General Meeting of Shareholders to Approve Merger With Leap Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 24 Nov 2016
Kymab Secures US$100 Million Series C Funding
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 23 Nov 2016
Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial
Biopharmaceuticals Neurology

HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Nov 2016
Regeneron and Sanofi Announce Praluent(R) (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2016
The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter
Biopharmaceuticals Cardiology

HSMN NewsFeed - 1 Nov 2016
Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
Biopharmaceuticals Cardiology

HSMN NewsFeed - 31 Oct 2016
European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Oct 2016
Astellas to Acquire Ganymed Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 26 Oct 2016
Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Oct 2016
Agilent Technologies Receives Expanded FDA Approval for Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Non-Small Cell Lung Cancer (NSCLC)
Diagnostics Oncology FDA

HSMN NewsFeed - 18 Oct 2016
True North Therapeutics Announces $45 Million Series D Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 12 Oct 2016
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 6 Oct 2016
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2016
EUSA Pharma Acquires Global Rights to Neuroblastoma Treatment Isqette(R) (Dinutuximab Beta) from Apeiron Biologics
Biopharmaceuticals Oncology Acqusitions

HSMN NewsFeed - 3 Oct 2016
Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 29 Aug 2016
Leap Therapeutics and Macrocure Announce Definitive Merger Agreement
Biopharmaceuticals Wound Care Mergers & Acquisitions

HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology

HSMN NewsFeed - 8 Aug 2016
Takeda Receives Marketing Authorization in Canada for NINLARO(TM) (ixazomib) in Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jul 2016
Amgen and UCB Submit Biologics License Application for Romosozumab to the FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Jul 2016
ContraFect Corporation Names Steven C. Gilman, PhD Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 18 Jul 2016
Genentech Provides Update on Phase III Study of Gazyva(R) in People With Previously Untreated Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jul 2016
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Jul 2016
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 1 Jul 2016
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
Biopharmaceuticals Licensing

HSMN NewsFeed - 29 Jun 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Jun 2016
Oncternal Therapeutics Merges with Tokalas to Form Clinical-Stage Biotechnology Company with Promising Oncology Pipeline
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 11 May 2016
Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 9 May 2016
Synthetic Biologics Appoints Deb Mathews, PharmD, as Vice President, Medical Affairs
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA

HSMN NewsFeed - 18 Apr 2016
AnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Biopharmaceuticals Personalized Medicine Oncology FDA

HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Diagnostics Oncology Regulatory

HSMN NewsFeed - 4 Apr 2016
European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix(TM), XBiotech’s True Human(TM) Therapeutic Antibody Treatment for Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 23 Mar 2016
Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing
Biopharmaceuticals Ophthalmology Venture Capital

HSMN NewsFeed - 21 Mar 2016
Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis
Biopharmaceuticals

HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 15 Mar 2016
Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study
Biopharmaceuticals Neurology

HSMN NewsFeed - 11 Mar 2016
Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 8 Mar 2016
Medgenics Hires Rick Couch, Ph.D. to Vice President of Chemistry, Manufacturing and Controls
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Mar 2016
3SBio Inc. Announces Expansion of its Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Mar 2016
Merck KGaA, Darmstadt, Germany Initiates Phase III Study of MSB11022, a Proposed Biosimilar of Adalimumab, in Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 29 Feb 2016
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
Biopharmaceuticals

HSMN NewsFeed - 26 Feb 2016
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Feb 2016
Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs
Biopharmaceuticals Oncology Venture Capital Licensing

HSMN NewsFeed - 22 Feb 2016
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Biopharmaceuticals

HSMN NewsFeed - 17 Feb 2016
FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 9 Feb 2016
Aytu BioScience Announces First Commercial Sales for Company's MiOXSYS(TM) System for Male Infertility
Devices Urology Product Launch

HSMN NewsFeed - 9 Feb 2016
Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Feb 2016
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha(R) (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Biopharmaceuticals

HSMN NewsFeed - 3 Feb 2016
ProMIS Neurosciences announces identification of a second novel therapeutic target for Alzheimer's disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 27 Jan 2016
Aytu BioScience Announces Additions to Board of Directors
Biopharmaceuticals Urology Personnel

HSMN NewsFeed - 25 Jan 2016
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 Jan 2016
Acorda to Acquire Biotie Therapies
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 18 Jan 2016
iCo Strategic Reorganization
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Jan 2016
Aytu BioScience Obtains CE Marking for Company's MiOXSYS(TM) System for Male Infertility
Biopharmaceuticals Urology Regulatory

HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Dec 2015
Merck KGaA, Darmstadt, Germany, Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Dec 2015
Amgen's First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501
Biopharmaceuticals Regulatory

HSMN NewsFeed - 3 Dec 2015
True North Therapeutics Announces $40 Million Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 18 Nov 2015
Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals

HSMN NewsFeed - 4 Nov 2015
Vaccinogen Promotes Peter Morsing, Ph.D. to Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Nov 2015
Shire to Acquire Dyax Corp, Expanding and Extending Industry-Leading Hereditary Angioedema (HAE) Portfolio
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 23 Oct 2015
Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for EVOMELA(TM) (melphalan) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Oct 2015
Sorrento Expands its Executive Management Team with Appointment of Dr. Jeffrey Su as Chief Operating Officer to Lead its in-house Bioprocess and Manufacturing Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 15 Oct 2015
Biothera Appoints Dr. Jose Iglesias as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 9 Oct 2015
Adheron Therapeutics to be acquired by Roche
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 1 Oct 2015
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Sep 2015
Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions

HSMN NewsFeed - 11 Sep 2015
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha(TM) (Evolocumab)
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 10 Sep 2015
Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 4 Sep 2015
U.S. FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Sep 2015
ADC Therapeutics Secures $80m Financing to Progress Its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 1 Sep 2015
Valeant And AstraZeneca To Partner On Brodalumab
Biopharmaceuticals Dermatology Licensing Distribution

HSMN NewsFeed - 27 Aug 2015
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Aug 2015
Alder BioPharmaceuticals Appoints Paul B. Cleveland to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Aug 2015
Immunomedics Appoints Arthur S. Kirsch as Director
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Aug 2015
Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune
Biopharmaceuticals Licensing

HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Aug 2015
Hetero Announces the Launch of Biosimilar Rituximab (MABALL(TM)) in India
Biopharmaceuticals Generics Oncology Product Launch

HSMN NewsFeed - 3 Aug 2015
CytomX Announces Management Team Promotions
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 31 Jul 2015
Xencor Appoints Yujiro S. Hata to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jul 2015
Oncobiologics Secures $31 Million Financing to Advance BioSymphony(TM) Platform Development and Monoclonal Antibody Biosimilars Pipeline
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce FDA Approval of Praluent(R) (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 Jul 2015
Sorrento Announces Departure of Mr. George Uy to become CEO of Start-up Company
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Jul 2015
Immunocore Secures $320 Million (£205 Million) in Europe's Largest Private Life Sciences Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 14 Jul 2015
Aridis Pharmaceuticals Appoints Fred Kurland as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Jul 2015
In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Bladder Cancer
Biopharmaceuticals Oncology Urology

HSMN NewsFeed - 30 Jun 2015
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif(R)) in Two Phase III Studies in Multiple Sclerosis
Biopharmaceuticals Neurology

HSMN NewsFeed - 16 Jun 2015
Kezar Life Sciences Closes $23M Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 21 May 2015
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 13 May 2015
Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 May 2015
Aspyrian Therapeutics Inc. Announces FDA Acceptance of an Investigational New Drug Application for RM-1929, a First-in-Class, Precision-Targeted Therapy for Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution

HSMN NewsFeed - 23 Apr 2015
Jounce Therapeutics Secures $56 Million in Oversubscribed Series B Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 7 Apr 2015
True North Therapeutics Announces $35 Million Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 6 Apr 2015
European Commission Approves Amgen's Vectibix(R) (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 3 Apr 2015
MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 27 Mar 2015
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 Mar 2015
Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Feb 2015
Compugen Expands and Strengthens Business Development Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 Feb 2015
Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Jan 2015
Regeneron and Sanofi Announce Praluent(TM) (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Dec 2014
Zydus Launches World's First Biosimilar of Adalimumab
Biopharmaceuticals Product Launch

HSMN NewsFeed - 23 Sep 2014
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Sep 2014
Successful Completion of Phase III Program for Teva’s Reslizumab Two More Phase Iii Studies Support the Benefits of Reslizumab Treatment in Asthma Patients with Eosinophilia
Biopharmaceuticals

HSMN NewsFeed - 3 Sep 2014
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Jun 2014
RuiYi Closes $4 Million Venture Loan from Silicon Valley Bank
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 27 May 2014
Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody(TM) Therapeutics Against Multiple Immuno-Oncology Targets
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Apr 2014
Bristol-Myers Squibb Acquires iPierian, Inc.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 28 Apr 2014
Actinium Announces Key Additions to Senior Management Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Apr 2014
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Apr 2014
Epirus and Zalicus Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions Venture Capital

HSMN NewsFeed - 14 Apr 2014
Synthetic Biologics Appoints Mark Pimentel, M.D., Chairman of New Irritable Bowel Syndrome Clinical Advisory Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Apr 2014
EMBL Ventures Invests £2M ($3.3M) in a Second Close of Crescendo Biologics' Series A Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 2 Apr 2014
Immune CEO Announces New Operational Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 26 Mar 2014
Kolltan Pharmaceuticals Obtains $60 Million in Series D Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 21 Mar 2014
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 11 Mar 2014
Sorrento Therapeutics Appoints Mark Durand to its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Mar 2014
Stem Cell Therapeutics Strengthens its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Mar 2014
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Feb 2014
CoStim Pharmaceuticals, Inc. Acquired by Novartis
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 12 Feb 2014
Osiris Therapeutics Promotes Frank Czworka to Vice President and General Manager of Wound Care
Devices Regenerative Medicine Wound Care Personnel

HSMN NewsFeed - 3 Feb 2014
PDL BioPharma Announces Agreement with Genentech and Roche to Settle Litigation and Arbitration
Biopharmaceuticals Litigation

HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Jan 2014
Biothera Names VP of Biomarker Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Jan 2014
Synthetic Biologics Strengthens Clinical & Regulatory Team to Support Expanding Pipeline of Infectious Disease Programs
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 13 Jan 2014
Agenus Appoints Robert B. Stein, MD, PhD, as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 13 Jan 2014
Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 9 Jan 2014
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Jan 2014
CytomX Therapeutics and ImmunoGen, Inc. Announce Strategic Collaboration to Develop Probody-Drug Conjugates Against Cancer Targets
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Jan 2014
Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Jan 2014
KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Jan 2014
Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 6 Jan 2014
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Dec 2013
Senesco Announces Letter of Intent to Merge with Fabrus
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 23 Dec 2013
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 17 Dec 2013
Crescendo Biologics Raises £17.5M ($28M) in Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 9 Dec 2013
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 4 Dec 2013
TherapeuticsMD Appoints Joel S. Krasnow, M.D. as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Dec 2013
Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Dec 2013
Visterra Closes $8.1 Million Financing and Expands Executive Team to Accelerate Company Growth
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 22 Nov 2013
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Biopharmaceuticals

HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Biopharmaceuticals

HSMN NewsFeed - 7 Nov 2013
Salix Pharmaceuticals to Acquire Santarus
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 7 Nov 2013
ImmunGene Raises $9 Million in Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 1 Nov 2013
FDA Approves Gazyva (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Oct 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation for the Use of Tigecycline to Treat Acute Myeloid Leukemia
Regenerative Medicine Oncology FDA

HSMN NewsFeed - 4 Oct 2013
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Sep 2013
Perrigo Company Appoints FDA Veteran As New Head Of Regulatory Review
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Sep 2013
Actinium Pharmaceuticals Appoints Corey Sohmer As Vice President Of Finance And Business Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
Biopharmaceuticals Neurology Regulatory

HSMN NewsFeed - 16 Sep 2013
Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Sep 2013
Kolltan Pharmaceuticals Appoints Carolyn F. Sidor, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Sep 2013
$30 Million Secured in iPierian Financing and Series A Financing for Launch of Spin-out, True North Therapeutics
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 3 Sep 2013
Arsanis Inc Closes $20 Million Series B Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 12 Aug 2013
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Aug 2013
KaloBios Appoints V. Bryan Lawlis, Jr., Ph.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Aug 2013
James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
Biopharmaceuticals Drug Delivery Ophthalmology Personnel

HSMN NewsFeed - 26 Jul 2013
Meditope Biosciences Raises $3.6M in Series A Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 26 Jul 2013
Adimab Announces First Antibody Technology Transfer and License Agreement with GlaxoSmithKline
Biopharmaceuticals Licensing

HSMN NewsFeed - 24 Jul 2013
PDL BioPharma Appoints David Montez as Controller and Chief Accounting Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Jul 2013
Instrumentation Laboratory Launches HemosIL(R) FDP Assay In Europe, Asia And Other International Regions
Diagnostics Product Launch

HSMN NewsFeed - 15 Jul 2013
Visterra Appoints Brian Pereira, M.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Jul 2013
Pfizer Provides Update on Global Regulatory Approvals and Launches of XELJANZ(R) (tofacitinib citrate) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Biopharmaceuticals Neurology Regulatory

Return to NewsFeed

Additional items found! 500

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 500 additional stories matching:
monoclonal
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!